AXSM Q3 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$171M+63.2% YoY

Gross Profit

$159M93.0% margin

Operating Income

-$46M-27.0% margin

Net Income

-$47M-27.6% margin

EPS (Diluted)

$-0.94

QoQ Revenue Growth

+14.0%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$988,000

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$669M

Total Liabilities

$596M

Stockholders' Equity

$74M

Cash & Equivalents

$325M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$171M	$105M	+63.2%
Gross Profit	$159M	$96M	+65.1%
Operating Income	-$46M	-$63M	+26.4%
Net Income	-$47M	-$65M	+26.9%

Revenue Segments

Product

$170M99%

Royalty

$2M1%

Geographic Segments

UNITED STATES

$169M99%

Non-US

$1M1%